Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merav Leiba

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Palliative Medicine|March 25, 2021
Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapyLiza Barki-Harrington, Orna Baron-Epel, Adir Shaulov, et al.
Haematologica|June 30, 2011
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myelomaJana Jakubikova, David Cervi, Melissa Ooi, et al.
Blood|February 16, 2011
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implicationsJana Jakubikova, Sophia Adamia, Maria Kost-Alimova, et al.
Leukemia & Lymphoma|September 8, 2022
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study GroupChezi Ganzel, Svetlana Trestman, Shai Levi, et al.
British Journal of Haematology|February 2, 2013
Cytogenetics of extramedullary manifestations in multiple myelomaLisa Billecke, Eva M Murga Penas, Annette M May, et al.
British Journal of Haematology|October 7, 2022
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective studyTamir Shragai, Hila Magen, Noa Lavi, et al.
Leukemia|February 1, 2020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyNizar J Bahlis, Meletios A Dimopoulos, Darrell J White, et al.
Leukemia & Lymphoma|September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experienceYafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.
Seminars in Hematology|May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathyShirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.
Blood|October 2, 2007
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuYu-Tzu Tai, Myles Dillon, Weihua Song, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Palliative Medicine|March 25, 2021
Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapyLiza Barki-Harrington, Orna Baron-Epel, Adir Shaulov, et al.
Haematologica|June 30, 2011
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myelomaJana Jakubikova, David Cervi, Melissa Ooi, et al.
Blood|February 16, 2011
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implicationsJana Jakubikova, Sophia Adamia, Maria Kost-Alimova, et al.
Leukemia & Lymphoma|September 8, 2022
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study GroupChezi Ganzel, Svetlana Trestman, Shai Levi, et al.
British Journal of Haematology|February 2, 2013
Cytogenetics of extramedullary manifestations in multiple myelomaLisa Billecke, Eva M Murga Penas, Annette M May, et al.
British Journal of Haematology|October 7, 2022
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective studyTamir Shragai, Hila Magen, Noa Lavi, et al.
Leukemia|February 1, 2020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyNizar J Bahlis, Meletios A Dimopoulos, Darrell J White, et al.
Leukemia & Lymphoma|September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experienceYafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.
Seminars in Hematology|May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathyShirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.
Blood|October 2, 2007
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuYu-Tzu Tai, Myles Dillon, Weihua Song, et al.
Pageof 7